文献速递肾移植肾小球疾病

抗肾小球基底膜疾病患者肾移植后的结局

Outcomes After Kidney Transplantation in Antiglomerular Basement Membrane Disease.
PubMed 文献 · Kidney Int Rep · 2025-06-18

这项回顾性多中心研究纳入2005至2023年法国13个移植中心的100例抗GBM肾小球肾炎(GBM-GN)肾移植患者,匹配200例对照。两组在移植肾功能延迟恢复、移植物存活、患者存活上无显著差异,GBM-GN组急性排斥风险呈较低趋势,仅1例复发。

要点

  • GBM-GN组与对照组移植肾功能延迟恢复发生率无显著差异(22% vs 19%,P=0.5)。
  • 5年移植物存活(87% vs 88%,P=0.4)与患者存活(93% vs 89%,P=0.4)均无显著差异。
  • GBM-GN组急性排斥风险呈较低趋势(HR=0.51,95%CI 0.25-1.02,P=0.055),仅1例(1%)复发。

核心结论

  • 在当前时代,GBM-GN患者肾移植的结局与其他肾病相当。
  • 疾病复发罕见,即使在移植前可检测到抗体的少数患者中也是如此。
  • GBM-GN组急性排斥发生率较低,值得进一步研究。
  • 这些发现支持肾移植是GBM-GN患者的可行选择,但建议进行特定的移植前和移植后监测。

研究设计与样本

  • 回顾性、多中心研究,纳入2005年至2023年在法国13个移植中心接受肾移植的100例抗GBM患者,匹配200例对照受者。
  • 比较两组移植肾功能延迟恢复、移植物失败、复发、急性排斥和死亡的发生率,并使用多变量模型分析危险因素。

主要发现

  • 移植肾功能延迟恢复发生率:GBM-GN组22% vs 对照组19%,P=0.5,无显著差异。
  • 5年移植物存活率:GBM-GN组87% vs 对照组88%,P=0.4,无显著差异。
  • 5年患者存活率:GBM-GN组93% vs 对照组89%,P=0.4,无显著差异。
  • 急性排斥风险:GBM-GN组HR=0.51(95%CI 0.25-1.02,P=0.055),呈较低趋势。
  • GBM-GN组仅1例(1%)出现疾病复发。

临床怎么用

  • 这些发现支持肾移植是GBM-GN患者的可行选择,但建议进行特定的移植前和移植后监测。

局限性

  • GBM-GN组急性排斥发生率较低,值得进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Goodpasture disease, or antiglomerular basement membrane (anti-GBM) disease, is a rare autoimmune disorder that often leads to end-stage kidney disease (ESKD). Although kidney transplantation (KT) is the preferred treatment, concerns exist about disease recurrence and graft outcomes in patients with GBM-associated glomerulonephritis (GBM-GN). This study aimed to evaluate posttransplant outcomes in patients with GBM-GN compared with matched controls. METHODS: This retrospective, multicenter study included 100 patients with anti-GBM who received KT between 2005 and 2023 in 13 French transplant centers, matched with 200 control recipients. We compared the incidence of delayed graft function (DGF), graft failure, relapse, acute rejection, and death between groups and analyzed risk factors using multivariable models. RESULTS: No significant differences in DGF incidence (22% vs. 19%, P = 0.5), graft survival (87% vs. 88% at 5 years, P = 0.4), or patient survival (93% vs. 89% at 5 years, P = 0.4) were found between patients with GBM-GN and controls. Patients with GBM-GN tended to have lower risk of acute rejection (hazard ratio [HR] = 0.51, 95% confidence interval: 0.25-1.02, P = 0.055). Only 1 patient with GBM-GN (1%) experienced disease relapse. Although patients with GBM-GN were waitlisted and transplanted later than controls, specific transplant timing was not associated with improved outcomes. CONCLUSION: KT in patients with GBM-GN offers comparable outcomes to other nephropathies in the current era. Disease relapse is rare, even in the few patients with detectable antibodies pretransplantation. The lower incidence of acute rejection in the GBM-GN group warrants further investigation. These findings support KT as a viable option in patients with GBM-GN, though specific pre- and posttransplant monitoring is advised.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Traversat P, Dekervel M, Masset C, et al. Outcomes After Kidney Transplantation in Antiglomerular Basement Membrane Disease. Kidney Int Rep. 2025. PMID: 40980652. doi:10.1016/j.ekir.2025.06.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。